Living EuroGuiDerm Guideline for the systemic treatment of psoriasis vulgaris
The general recommendations developed in this guideline are based on the Living Cochrane review published in January 2020. With new evidence and new results becoming available, the guideline development group will consider these and decide if and when an update is necessary. This will also be the case for the recommendations for specific clinical and comorbid situations.
Contains intructions for use, recommendations for lab controls, adverse drug reactions, special consideration during treatment, important contraindications and drug interactions